Visual Abstract

Introduction: The lifespan of patients with Fabry disease (FD) is shorter than that seen in the general population. Leukocyte telomere length (LTL) and telomerase activity (TA) are potential markers of biologic aging. The aim of the current study was to determine the LTL and TA in FD patients and to assess the correlation between LTL and TA and renal involvement. Methods: We included 33 FD patients and 66 healthy matched controls. LTL and TA were measured using a quantitative PCR assay and gene expression assay. FD patients were stratified by renal function (estimated glomerular filtration rate [eGFR] higher or lower than 60 mL/min/1.73 m2) and proteinuria (urine protein creatinine ratio higher or lower than 0.5 g/g). Results: LTL was significantly shorter (0.69 vs. 0.73, p = 0.015) and TA significantly higher (1.55 vs. 1.19, p = 0.047) in FD patients compared to controls. Males with FD had significantly shorter LTL (p = 0.020) and lower, but non-significant, TA compared to male controls (p = 0.333). Female FD patients had similar LTL (p = 0.285) but significantly higher TA compared to female controls (p = 0.005). LTL was not influenced by eGFR, but TA was significantly lower in the low eGFR group (p = 0.003). Conclusions: FD patients have significantly shorter LTL, but significantly higher TA compared to healthy controls. Increased TA activity in FD patients could be the compensation mechanism to prevent LTL decrease (and accelerated ageing), which seems to be exhausted at the advanced stage of renal disease.

1.
Germain DP. Fabry disease.
Orphanet J Rare Dis
. 2010 Nov;5(1):30.
2.
Weidemann F, Sanchez-Niño MD, Politei J, Oliveira JP, Wanner C, Warnock DG, et al. Fibrosis: a key feature of Fabry disease with potential therapeutic implications.
Orphanet J Rare Dis
. 2013 Aug;8(1):116.
3.
Sanchez-Niño MD, Carpio D, Sanz AB, Ruiz-Ortega M, Mezzano S, Ortiz A. Lyso-Gb3 activates Notch1 in human podocytes.
Hum Mol Genet
. 2015 Oct;24(20):5720–32.
4.
Torra R, Ortíz A. Fabry disease: the many faces of a single disorder.
Clin Kidney J
. 2012 Oct;5(5):379–82.
5.
Waldek S, Feriozzi S. Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?
BMC Nephrol
. 2014 May;15(1):72.
6.
Talbot AS, Lewis NT, Nicholls KM. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
Heart
. 2015 Feb;101(4):287–93.
7.
Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry.
Genet Med
. 2009 Nov;11(11):790–6.
8.
Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, et al.; European FOS Investigators. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey.
Eur Heart J
. 2007 May;28(10):1228–35.
9.
Biancini GB, Vanzin CS, Rodrigues DB, Deon M, Ribas GS, Barschak AG, et al. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy.
Biochim Biophys Acta
. 2012 Feb;1822(2):226–32.
10.
Wang Q, Zhan Y, Pedersen NL, Fang F, Hägg S. Telomere Length and All-Cause Mortality: A Meta-analysis.
Ageing Res Rev
. 2018 Dec;48:11–20.
11.
Franceschi C, Bonafè M, Valensin S, Olivieri F, De Luca M, Ottaviani E, et al. Inflamm-aging. An evolutionary perspective on immunosenescence.
Ann N Y Acad Sci
. 2000 Jun;908(1):244–54.
12.
Kooman JP, Dekker MJ, Usvyat LA, Kotanko P, van der Sande FM, Schalkwijk CG, et al. Inflammation and premature aging in advanced chronic kidney disease.
Am J Physiol Renal Physiol
. 2017 Oct;313(4):F938–50.
13.
Kooman JP, Broers NJ, Usvyat L, Thijssen S, van der Sande FM, Cornelis T, et al. Out of control: accelerated aging in uremia.
Nephrol Dial Transplant
. 2013 Jan;28(1):48–54.
14.
Ameh OI, Okpechi IG, Dandara C, Kengne AP. Association Between Telomere Length, Chronic Kidney Disease, and Renal Traits: A Systematic Review.
OMICS
. 2017 Mar;21(3):143–55.
15.
Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts.
Nature
. 1990 May;345(6274):458–60.
16.
Georgin-Lavialle S, Aouba A, Mouthon L, Londono-Vallejo JA, Lepelletier Y, Gabet AS, et al. The telomere/telomerase system in autoimmune and systemic immune-mediated diseases.
Autoimmun Rev
. 2010 Aug;9(10):646–51.
17.
Blackburn EH. Switching and signaling at the telomere.
Cell
. 2001 Sep;106(6):661–73.
18.
von Zglinicki T. Oxidative stress shortens telomeres.
Trends Biochem Sci
. 2002 Jul;27(7):339–44.
19.
Mather KA, Jorm AF, Parslow RA, Christensen H. Is telomere length a biomarker of aging? A review.
J Gerontol A Biol Sci Med Sci
. 2011 Feb;66(2):202–13.
20.
Samani NJ, van der Harst P. Biological ageing and cardiovascular disease.
Heart
. 2008 May;94(5):537–9.
21.
Lin J, Epel E, Blackburn E. Telomeres and lifestyle factors: roles in cellular aging.
Mutat Res
. 2012 Feb;730(1-2):85–9.
22.
Stenvinkel P, Larsson TE. Chronic kidney disease: a clinical model of premature aging.
Am J Kidney Dis
. 2013 Aug;62(2):339–51.
23.
Kroenke CH, Pletcher MJ, Lin J, Blackburn E, Adler N, Matthews K, et al. Telomerase, telomere length, and coronary artery calcium in black and white men in the CARDIA study.
Atherosclerosis
. 2012 Feb;220(2):506–12.
24.
Zalli A, Carvalho LA, Lin J, Hamer M, Erusalimsky JD, Blackburn EH, et al. Shorter telomeres with high telomerase activity are associated with raised allostatic load and impoverished psychosocial resources.
Proc Natl Acad Sci USA
. 2014 Mar;111(12):4519–24.
25.
Shiels PG, Stenvinkel P, Kooman JP, -McGuinness D. Circulating markers of -ageing and allostatic load: A slow train -coming.
Pract Lab Med
. 2016 Apr;7(7):49–54.
26.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al.; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate.
Ann Intern Med
. 2009 May;150(9):604–12.
27.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Δ Δ C(T)) Method.
Methods
. 2001 Dec;25(4):402–8.
28.
Cawthon RM. Telomere measurement by quantitative PCR.
Nucleic Acids Res
. 2002 May;30(10):e47.
29.
Ravarotto V, Simioni F, Carraro G, Bertoldi G, Pagnin E, Calò LA. Oxidative Stress and Cardiovascular-Renal Damage in Fabry Disease: Is There Room for a Pathophysiological Involvement?
J Clin Med
. 2018 Nov;7(11):E409.
30.
Whybra C, Kampmann C, Willers I, Davies J, Winchester B, Kriegsmann J, et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes.
J Inherit Metab Dis
. 2001 Dec;24 7:715–24.
31.
Raschenberger J, Kollerits B, Titze S, Köttgen A, Bärthlein B, Ekici AB, et al.; GCKD study Investigators. Do telomeres have a higher plasticity than thought? Results from the German Chronic Kidney Disease (GCKD) study as a high-risk population.
Exp Gerontol
. 2015 Dec;72:162–6.
32.
Weischer M, Bojesen SE, Nordestgaard BG. Telomere shortening unrelated to smoking, body weight, physical activity, and alcohol intake: 4,576 general population individuals with repeat measurements 10 years apart.
PLoS Genet
. 2014 Mar;10 3:e1004191.
33.
Raschenberger J, Kollerits B, Ritchie J, Lane B, Kalra PA, Ritz E, et al. Association of relative telomere length with progression of chronic kidney disease in two cohorts: effect modification by smoking and diabetes.
Sci Rep
. 2015 Jul;5(1):11887.
34.
Melicher D, Buzas EI, Falus A. Genetic and epigenetic trends in telomere research: a novel way in immunoepigenetics.
Cell Mol Life Sci
. 2015 Nov;72 21:4095–109.
35.
Brouilette S, Singh RK, Thompson JR, Goodall AH, Samani NJ. White cell telomere length and risk of premature myocardial infarction.
Arterioscler Thromb Vasc Biol
. 2003 May;23 5:842–6.
36.
Kanasaki K, Kitada M, Koya D. Pathophysiology of the aging kidney and therapeutic interventions.
Hypertens Res
. 2012 Dec;35(12):1121–8.
37.
Koopman JJ, Rozing MP, Kramer A, de Jager DJ, Ansell D, De Meester JM, et al. Senescence rates in patients with end-stage renal disease: a critical appraisal of the Gompertz model.
Aging Cell
. 2011 Apr;10(2):233–8.
38.
Tsirpanlis G, Chatzipanagiotou S, Boufidou F, Kordinas V, Alevyzaki F, Zoga M, et al. Telomerase activity is decreased in peripheral blood mononuclear cells of hemodialysis patients.
Am J Nephrol
. 2006;26(1):91–6.
39.
Tsakiris D, Simpson HK, Jones EH, Briggs JD, Elinder CG, Mendel S, et al. Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry.
Nephrol Dial Transplant
. 1996;11 Suppl 7:4–20.
40.
Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores GM, et al. Patients with Fabry disease on dialysis in the United States.
Kidney Int
. 2002 Jan;61(1):249–55.
41.
Sharma A, Sartori M, Zaragoza JJ, Villa G, Lu R, Faggiana E, et al. Fabry’s disease: an example of cardiorenal syndrome type 5.
Heart Fail Rev
. 2015 Nov;20(6):689–708.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.